Leukemia Research

Papers
(The TQCC of Leukemia Research is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Editorial Board55
Bortezomib-resistant multiple myeloma patient-derived xenograft is sensitive to anti-CD47 therapy32
MDS AND AUTO-IMMUNITY29
DISTINCT PATHOGENESIS OF CLONAL HEMATOPOIESIS REVEALED BY SINGLE-CELL MULTI-OMICS SEQUENCING28
CHARACTERIZATION OF TRANSCRIPTIONAL ALTERATIONS LEADING TO ABERRANT MYELOID DIFFERENTIATION IN MYELODYSPLASTIC SYNDROMES21
5-AZACYTIDINE IN COMBINATION WITH A NOVEL PAN-LYSYL OXIDASE INHIBITOR SYNERGISTICALLY RESTORES ERYTHROPOIESIS IN MYELODYSPLASTIC MALIGNANCIES20
Topic: AS04-MDS Biology and Pathogenesis/AS04a-Normal, MDS, and leukemic stem cells: DER(1;7)(Q10;P10) DEFINES A DISTINCT SUBTYPE OF MYELODYSPLASIA19
Topic: AS01-Diagnosis/AS01a-Cytomorphology: ARTIFICIAL INTELLIGENCE MAY HELP THE HEMATOPATHOLOGIST IN EVALUATION OF BONE MASS AND CELLULARITY IN BONE MARROW SPECIMENS OF PATIENTS WITH MDS19
Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation/inflammation: HIGHER LEPTIN LEVEL IS ASSOCIATED WITH MYELODYSPLASTIC SYNDROME: A COMPARATIVE STUDY18
Topic: AS04-MDS Biology and Pathogenesis/AS04i-Microenvironment and stem cell niche: MESENCHYMAL STROMAL CELLS OF THE BONE MARROW NICHE CONTRIBUTE TO THE PROINFLAMMATORY PHENOTYPE OF CMML MONOCYTES TH18
Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: A STEP TOWARDS IDENTIFICATION AND CAUSAL INTERPRETATION OF THERAPY-RELATED MDS (T-MDS)17
DDGP followed by radiotherapy vs VIPD followed by radiotherapy in newly diagnosed early NK/T-cell lymphoma15
Editorial Board15
EFFICACY AND SAFETY OF SEQUENTIAL DIFFERENT B CELL ANTIGEN-TARGETED CAR T-CELL THERAPY FOR PEDIATRIC REFRACTORY/ RELAPSED BURKITT LYMPHOMA WITH SECONDARY CENTRAL NERVOUS SYSTEM INVOLVEMENT15
ALK INHIBITORS SAFETY PROFILE IN PEDIATRIC PATIENTS TREATED FOR AN ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA: REAL LIFE EXPERIENCE AMONG A FRENCH COHORT15
TARGETED THERAPY INCREASES PD-L1 PROTEIN EXPRESSION IN CELL LINES OF MEDIASTINAL LYMPHOMA14
Prognostic value of ASXL1 mutations in acute myeloid leukemia: A meta-analysis14
SOX11 AND EPSTEIN–BARR VIRUS MAY SUBSTITUTE EACH OTHER IN EARLY PATHOGENESIS OF BURKITT LYMPHOMA14
Association of minimal residual disease levels with clinical outcomes in patients with mantle cell lymphoma: A meta-analysis14
Topic: AS01-Diagnosis/AS01a-Cytomorphology14
Time to first treatment is an independent prognostic factor for Multiple Myeloma (MM)13
Acute leukemias with complex karyotype show a similarly poor outcome independent of mixed, myeloid or lymphoblastic immunophenotype: A study from the Bone Marrow Pathology Group13
Acquired alpha thalassemia associated with myeloid malignancy: A systematic literature review13
A phase I clinical trial of lenalidomide combined with bortezomib for acute myeloid leukemia or myelodysplastic syndrome relapsing after allogeneic stem cell transplantation13
Ruxolitinib discontinuation in polycythemia vera: Patient characteristics, outcomes, and salvage strategies from a large multi-institutional database13
How low can you go?: Methodologic considerations in clonal hematopoiesis variant calling13
Comparison of a modified pediatric protocol versus a hyper-CVAD protocol in adolescents and young adults with Philadelphia-negative acute lymphoblastic leukemia: A multicenter retrospective analysis12
Outcomes with high dose cytarabine and mitoxantrone induction for adults with mixed phenotype acute leukemia12
Measurable residual disease by flow cytometry in acute myeloid leukemia is prognostic, independent of genomic profiling12
Incidence and predictors of anthracycline-related left ventricular dysfunction in acute myeloid leukemia12
Topic: AS08-Treatment/AS08a-Current treatment options - Hypomethylating agents11
ACCELERATED RNA SPLICING DYNAMICS DURING ERYTHROID DIFFERENTIATION AMPLIFY MIS-SPLICING IN SF3B1-MUTANT MDS-RS11
Poster Pitch Presentations11
Changing frontline AML treatment patterns from 2013 to 202211
Topic: AS08-Treatment/AS08g-Clinical trials - Phase II-III11
Topic: AS04-MDS Biology and Pathogenesis/AS04f-Gene expression profiling: CMML PATIENTS WITH LOW EXPRESSION OF TP53 POINT TO AML TRANSFORMATION11
Editorial Board10
Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: INCREASED DNA-CELL-CYCLE S-PHASE FRACTION IS RELATED TO INCREASED INCIDENCES OF IMMATURE MYELOID CELLS AND HIGH IPSS-R RI10
ALK+ ALCL EVADES IMMUNE SURVEILLANCE THROUGH NPM-ALK-DRIVEN EPIGENETIC REPRESSION OF Cd4810
IMPACT OF RITUXIMAB ON IMMUNE STATUS FOLLOWING THERAPY IN CHILDREN AND ADOLESCENTS WITH HIGH-RISK MATURE B-CELL NON-HODGKIN LYMPHOMA: RESULTS OF THE INTER-B-NHL RITUX 2010 TRIAL10
Presentation name: Supportive Care10
Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment10
FULMINANT, EBV DRIVEN PLASMACYTIC POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER (PTLD) WITH LOSS OF 1P AND GAIN OF TP53/CEP17 AND IGH BONE MARROW INVOLVEMENT AFTER LIVER TRANSPLANT IN 17-MONTH OLD BOY9
MCL-1 INHIBITORS INDUCES APOPTOSIS IN VITRO IN BURKITT LYMPHOMA CELL LINES AND INHIBITS IN VIVO BURKITT LYMPHOMA PROGRESSION9
Donor matters: Donor selection impact on hematopoietic stem cell transplantation outcomes in Hispanic patients with B-cell acute lymphocytic leukemia: Insights from a myeloablative HSCT study9
Cost-effectiveness of blinatumomab for the treatment of B‑precursor acute lymphoblastic leukemia pediatric patients with high‑risk first‑relapse in Mexico9
Tyrosine kinase inhibitors combined with venetoclax and azacytidine as an effective therapy for de novo lymphoid blast phase-chronic myeloid leukemia9
Topic: AS08-Treatment/AS08b-Current treatment options – Lower risk MDS: PHASE 1 STUDY EVALUATING LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) P9
PRE-TRANSPLANT TREATMENT OF HEPATISPLENIC T-CELL LYMPHOMA (GAMMA-DELATA): A PEDIATRIC CASE REPORT9
FDG-PET/CT IMAGING IN PEDIATRIC PRECURSOR B-CELL LYMPHOBLASTIC LYMPHOMA (BCP-LBL) SHOWS BONE (MARROW) INVOLVEMENT IN A VAST MAJORITY OF PATIENTS9
Identification of ZNF384 as a regulator of epigenome in leukemia9
Canadian real-world experience of asciminib treatment in heavily pre-treated chronic myeloid leukemia (CML) patients who failed multiple lines of tyrosine kinase inhibitor (TKI) therapy9
Topic: AS09-Quality of life-Disease experiences: ANEMIA OF CHRONIC DISEASE IN THE ELDERLY: EVALUATION OF HEPCIDIN EXPRESSION AND ITS RELATIONSHIP WITH PROINFLAMMATORY CYTOKINES AND CLINICAL AND LABORA9
A RARE CASE OF PRIMARY OCULAR POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER IN A BRAZILIAN CHILD9
The impact of different FLT3-inhibitors on overall survival of de novo acute myeloid leukemia: A network meta-analysis9
Roles of noncoding RNAs in multiple myeloma9
Allogeneic stem cell transplant with TBI-based myeloablative conditioning in adolescents and young adults with Philadelphia chromosome-negative ALL treated with pediatric protocols9
Hyperleukocytosis in patients with acute myeloid leukemia admitted to the intensive care unit: a single-center retrospective analysis8
Triplet therapy with gilteritinib, venetoclax, and azacitidine for relapsed/refractory FLT3 acute myeloid leukemia8
Canadian evidence-based guideline for treatment of relapsed/refractory chronic lymphocytic leukemia8
SAMHD1 mutations in mantle cell lymphoma are recurrent and confer in vitro resistance to nucleoside analogues8
Impact of spliceosome mutation on outcomes of myelodysplastic syndrome and chronic myelomonocytic leukemia patients undergoing allogeneic hematopoietic cell transplantation8
A randomized, phase II trial of adjuvant immunotherapy with durable TKI-free survival in patients with chronic phase CML8
Overview of clinical and genetic features of CML patients with variant Philadelphia translocations involving chromosome 7: A case series8
Pregnancy and long-term outcomes of female patients with chronic myeloid leukemia on tyrosine kinase inhibitors who experienced unplanned pregnancies8
A machine learning approach to predicting risk of myelodysplastic syndrome8
Alternative strategies for optimizing treatment of chronic lymphocytic leukemia with complex clonal architecture8
Cutaneous manifestations of large granular lymphocytic leukemia: A case report and systematic review8
LncRNA MEG3 promotes the sensitivity of bortezomib by inhibiting autophagy in multiple myeloma7
Efficacy and safety of bosutinib in patients treated with prior imatinib and/or dasatinib and/or nilotinib: Subgroup analyses from the phase 4 BYOND study7
VARIANT ALK-FUSION POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA (ALCL): A POPULATION-BASED COHORT OF THE NHL-BFM STUDY GROUP7
CURRENT CARDIOVASCULAR DISEASE (CVD) RISK PREDICTION MODELS ARE NOT APPLICABLE IN MDS PATIENTS: PRELIMINARY RESULTS OF A PROSPECTIVE OBSERVATIONAL SINGLE-CENTRE COHORT STUDY7
Topic: AS04-MDS Biology and Pathogenesis/AS04b-Clonal diversity & evolution: INTEGRATED ANALYSIS OF MDS-OMICS INFORMS ON DRUG RESPONSE PROFILES7
Genetic changes during leukemic transformation to secondary acute myeloid leukemia from myeloproliferative neoplasms7
Impact of the quantity and quality of the skeletal muscle on survival among patients undergoing allogeneic hematopoietic stem cell transplantation7
First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemia7
Thiotepa-busulfan-fludarabine conditioning as a promising approach prior to haploidentical allogeneic hematopoietic stem cell transplantation in hematological malignancies with extramedullary involvem7
Topic: AS07-Singular Entities/Subtypes/AS07a-ARCH, CCUS, ICUS: PREVALENCE, DYNAMICS AND CLINICAL SIGNIFICANCE OF CLONAL HEMATOPOIESIS OF INDETERMINATE POTENTIAL (CHIP) IN NEWLY DIAGNOSED CANCER PATIEN7
PYRIMETHAMINE, A STAT3 INHIBITOR, HAS SYNERGY WITH VENETOCLAX AND IS EFFICACIOUS IN HYPOMETHYLATING AGENT RESISTANT MDS/AML7
Topic: AS01-Diagnosis/AS01b-Flow cytometry: IMMUNOPHENOTYPIC BONE MARROW CHARACTERISTICS IN MYELODYPLASTIC SYNDROME WITH SF3B1 MUTATION7
Accurate detection of subclonal variants in paired diagnosis-relapse acute myeloid leukemia samples by next generation Duplex Sequencing7
MiR-409–3p regulates the proliferation and apoptosis of THP-1 through targeting Rab107
Corrigendum to “Bortezomib-resistant multiple myeloma patient-derived xenograft is sensitive to anti-CD47 therapy” [Leuk. Res. 122 (2022) 106949]7
Topic: AS07-Singular Entities/Subtypes/AS07c-Hereditary MDS including predisposition syndromes: SECONDARY FINDINGS IN EXOME SEQUENCING IN 240 EARLY-ONSET ADULT MYELODYSPLASTIC SYNDROMES WITHOUT PREVIO7
Topic: AS01-Diagnosis/AS01a-Cytomorphology: DIAGNOSTIC CHALLENGE BETWEEN WHO AND ICC CLASSIFICATION7
Editorial Board7
Advances in diagnosis, treatment and prognostic factors of gastrointestinal DLBCL7
Topic: AS08-Treatment/AS08b-Current treatment options – Lower risk MDS: LUSPATERCEPT IN LOWER-RISK MDS TRANSFUSION-DEPENDENT PATIENTS; A SINGLE-CENTRE EXPERIENCE6
PRINCIPAL ACTIONS OF THE MYELODYSPLASTIC SYNDROME HSCT AMERICAN LATIN REGISTRY6
Immunomolecular evaluation of dihydroartemisinin effects on apoptosis in chronic lymphocytic leukemia cell lines6
IMMUNOGLOBULIN SUBCLASSES OF ANTI-ALK ANTIBODIES IN PEDIATRIC ANAPLASTIC LARGE CELL LYMPHOMA6
Outcome of adolescents and young adult acute myeloid leukemia patients compared with middle-aged patients: A single centre retrospective experience6
Assessing the associations of blood metabolites with myelodysplastic syndrome: A bidirectional mendelian randomization study6
LncRNA landscape analysis identified LncRNA LEF-AS1 as an oncogene that upregulates LEF1 and promotes survival in chronic lymphocytic leukemia6
BONE MARROW INFILTRATION AS A PROGNOSTICE FACTOR IN PEDIATARIC BURKITT LYMPHOMA PATIENTS6
THE CHALLENGE OF PROSPECTIVE DISTINCTION BETWEEN NON-NEOPLASTIC VERUS NEOPLASTIC EBV-ASSOCIATED HLH6
Topic: AS08-Treatment/AS08h-Allogeneic hematopoietic cell transplantation -Bridging to transplantation6
Assessment of rituximab-abbs, a biosimilar, and rituximab outcomes in patients with CLL or NHL: A real-world UK study6
Sorafenib in combination with intensive chemotherapy for relapsed or refractory FLT3-ITD positive acute myeloid leukemia: A two centers experience6
Topic: AS04-MDS Biology and Pathogenesis/AS04i-Microenvironment and stem cell niche6
QOL6
SEARCHING FOR THE CAUSES OF ANAPLASTIC LARGE CELL LYMPHOMA6
Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosome‒positive leukemias6
PI3K/AKT inhibitor BEZ-235 targets CCND2 and induces G1 arrest in breast implant-associated anaplastic large cell lymphoma6
PEDIATRIC LOW GRADE LYMPHOMAS: A REPORT FROM A SINGLE CENTRE6
BCL2 FAMILY INHIBITORS6
Topic: AS04-MDS Biology and Pathogenesis/AS04f-Gene expression profiling: MUTATION-SPECIFIC HSPC ENRICHMENT PATTERNS UNDERLIE PROGNOSTICALLY SIGNIFICANT TRANSCRIPTOMIC SUBGROUPS OF MDS PATIENTS6
Longer-term response to SARS-CoV-2 vaccine in MPN patients: Role of ruxolitinib and disease severity6
Distinct mutational and clinicopathologic profiles characterize acute myeloid leukemia with cup-like nuclei6
Systematic review and meta-analysis evaluating clinical outcomes in adult acute myeloid leukemia patients with central nervous system involvement6
Retraction notice to “Low-dose radiotherapy (2×2 g) versus low doses and rituximab in the treatment of marginal zone b-cell lymphoma previously untreated” [Leuk. Res. 98C (2020) 106443]6
Impact of FLT3 inhibitors on the outcomes of FLT3-ITD mutated acute myeloid leukemia following allogeneic hematopoietic stem cell transplant: A systematic review and meta-analysis6
Real-world impact of luspatercept on red blood cell transfusions among patients with myelodysplastic syndromes: A United States healthcare claims database study6
Alternating venetoclax/azacytidine and FLT3 inhibitor treatment for NPM1- and FLT3-mutated acute myeloid leukemia6
Universal posttransplant cyclophosphamide after allogeneic transplant, a retrospective single institution study6
18F-FDG-PET/CT IN THE ASSESSMENT OF BONE MARROW INVOLVEMENT IN PEDIATRIC NON-HODGKIN LYMPHOMA- A SINGLE CENTER EXPEREIENCE6
Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation6
E-Poster Viewing5
Pre-transplant blinatumomab and/or inotuzumab ozogamicin therapy for relapsed/refractory acute lymphoblastic and B/myeloid mixed phenotype acute leukemia in adults5
Topic: AS04-MDS Biology and Pathogenesis/AS04f-Gene expression profiling5
Topic: AS04-MDS Biology and Pathogenesis/AS04b-Clonal diversity & evolution: LONG-TERM MUTATIONAL DYNAMICS IN DEL(5Q) MDS PATIENTS EARLY TREATED WTIH LENALIDOMIDE (SINTRAREV CLINICAL TRIAL). SAFE 5
Topic: AS04-MDS Biology and Pathogenesis/AS04i-Microenvironment and stem cell niche5
Topic: AS04-MDS Biology and Pathogenesis/AS04d-Somatic mutations: THE EVOLVING GENETIC LANDSCAPE OF PEDIATRIC MDS-EB5
Tumor-associated macrophages modulate angiogenesis and tumor growth in a xenograft mouse model of multiple myeloma5
Topic: AS01-Diagnosis/AS01b-Flow cytometry: COMMITTED AND IMMATURE ERYTHROID PROGENITORS ARE DIFFERENTLY DISTRIBUTED IN LOWER RISK MYELODYSPLASTIC SYNDROMES ACCORDING TO WHO CATEGORY AND CORRELATE WIT5
Immunological aspects of HTLV-1 persistence; for the prevention and treatment of Adult T-cell leukaemia-lymphoma (ATL)5
CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD1235
Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation5
Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment5
Topic: AS08-Treatment/AS08a-Current treatment options – Higher risk MDS: VENETOCLAX AND AZACYTIDINE IN HIGH-RISK MYELODYSPLASTIC SYNDROMES, A REAL-WORLD EXPERIENCE. LATIN-AMERICAN MDS GROUP – GLAM5
Philadelphia-positive B-lymphoblastic leukemia in a middle-income country – A real-world multicenter cohort5
Erratum to ‘Do patients with haematological malignancies suffer financial burden? A cross-sectional study of patients seeking care through a publicly funded healthcare system’ [Leukemia Research 112C 5
CHARACTERIZING THROMBOSIS IN CHILDREN & ADOLESCENTS WITH PRIMARY MEDIASTINAL B-CELL LYMPHOMA5
PEDIATRIC AND YOUNG ADULT ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA GENETICALLY DIFFERS FROM THE ADULT COUNTERPART5
A systematic review of second-generation FLT3 inhibitors for treatment of patients with relapsed/refractory acute myeloid leukemia5
Recent progress in pathological understanding of adult T-cell leukemia/lymphoma in the new classification era5
Topic: AS08-Treatment/AS08h-Allogeneic hematopoietic cell transplantation – Post-transplantation treatment: IN VIVO DUAL T CELL DEPLETION (TCD) IMPROVES TRANSPLANT OUTCOMES IN MYELODYSPLASTIC SYNDROME5
A critical evaluation of the EFS endpoint in AML: Does induction treatment failure timing have a profound impact on study design and results?5
Topic: AS08-Treatment/AS08h-Allogeneic hematopoietic cell transplantation - Bridging to transplantation5
Therapeutic advances for the management of adult T cell leukemia: Where do we stand?5
Combination of dociparstat sodium (DSTAT), a CXCL12/CXCR4 inhibitor, with azacitidine for the treatment of hypomethylating agent refractory AML and MDS5
Topic: AS04-MDS Biology and Pathogenesis/AS04i-Microenvironment and stem cell niche5
VARYING OUTCOMES OF MATURE T AND NK LYMPHOMA IN PEDIATRIC AND ADOLESCENT/YOUNG ADULT PATIENTS: A SINGLE INSTITUTION EXPERIENCE5
RITUXIMAB CLEARANCE IN PEDIATRIC PATIENTS WITH MAATURE B-CELL NON-HODGKIN LYMPHOMA5
Serum hypoalbuminemia is an independent prognostic factor in Chronic Myelomonocytic Leukemia (CMML),5
Topic: AS08-Treatment/AS08b-Current treatment options – Lower risk MDS: LUSPATERCEPT FOR PATIENTS WITH LOWER RISK MDS ADMITTED TO THE HEMATOLOGY DEPARTMENT OF THE COLENTINA CLINICAL HOSPITAL - DATA FR5
NAP1L5 promotes epithelial–mesenchymal transition by regulating PEG10 expression in acute myeloid leukaemia5
Topic: AS08-Treatment/AS08f-Clinical trials – Phase II-III: SELECT-MDS-1 TRIAL IN PROGRESS: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF TAMIBAROTENE/AZACITIDINE VS PLACEBO/AZACITID5
Editorial Board4
PDGFRβ DRIVES PROGRESSION BY ONCOGENE TRANSCRIPTION THROUGH STAT3/STAT5 HYPERACTIVATION IN ALCL4
Topic: AS07-Singular Entities/Subtypes/AS07c-Hereditary MDS including predisposition syndromes: BEYOND DDX41: DDH AND DHX HELICASES ARE MUTATED IN MDS4
PEDIATRIC INFRADIAPHRAGMATIC HODGKIN’S LYMPHOMA: A UNIQUE IDENTITY4
Major clinical response in a patient with leukemia cutis treated with the bromodomain inhibitor PLX51107 and azacitidine4
Association between myeloid disorders and adult onset-inflammatory syndromes, successful treatment with JAK-inhibitors: Case series and literature review4
Editorial Board4
Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation4
BCR EXPRESSION IN BURKITT LYMPHOMA: NEW INSIGHT IN MUTATIONAL LANDSCAPE4
Editorial Board4
Growth and dormancy control of myeloma cells by mesenchymal stem cells4
MicroRNA-211 attenuates cell proliferation in T-cell lymphoblastic lymphoma through targeting TCF124
ALK INIHIBITOR THERAPY IN ALCL4
Specific immune response to mRNA vaccines against COVID-19 in patients receiving allogeneic stem cell transplantation for myeloid malignancy was altered by immunosuppressive therapy4
Topic: AS08-Treatment/AS08b-Current treatment options – Lower risk MDS: SINGLE-CENTER EXPERIENCE WITH LUSPATERCEPT THERAPY IN LOW-RISK MYELODYSPLASTIC SYNDROME (LR-MDS) PATIENTS WITH TRANSFUSION DEPEN4
Safety, tolerability, and pharmacokinetics of ASP1235 in relapsed or refractory acute myeloid leukemia: A phase 1 study4
COVID-19 infection in adult and paediatric recipients of allogeneic stem cell transplantation: The UK experience4
The effect of body mass index on the safety of bosutinib in patients with chronic leukemia: A post hoc pooled data analysis4
Topic: AS04-MDS Biology and Pathogenesis/AS04d-Somatic mutations4
Topic: AS08-Treatment/AS08h-Allogeneic hematopoietic cell transplantation -Bridging to transplantation4
Unmutated IGHV at diagnosis in patients with early stage CLL independently predicts for shorter follow-up time to first treatment (TTFT)4
Alternative polyadenylation quantitative trait loci contribute to acute myeloid leukemia risk genes regulation4
Multiple cells of origin in common with various types of mouse N-Myc acute leukemia4
Proposal and clinical application of molecular genetic risk scoring system, “MRplus”, for BCR-ABL1 negative pediatric B-cell acute lymphoblastic leukemia- report from a single centre4
Topic: AS06-Prognosis/AS06b-Predictive factors of response to treatment: RESISTANCE TO HYPOMETHYLATING AGENTS (HMA) IN HIGH-RISK MYELODYSPLASTIC SYNDROME (HR-MDS): THE ROLE OF THE ADENOSINE DEAMINASE 4
Effect of single-unit transfusion in patients treated for haematological disease including acute leukemia: A multicenter randomized controlled clinical trial4
Gilteritinib in the management of acute myeloid leukemia: Current evidence and future directions4
Maternal obesity and acute lymphoblastic leukemia risk in offspring: A summary of trends, epidemiological evidence, and possible biological mechanisms4
Topic: AS08-Treatment/AS08a-Current treatment options - Hypomethylating agents4
AN UNUSUAL PRESENTATION OF A RARE PEDIATRIC DISEASE4
Outcomes of patients with acute myeloid leukemia treated with intensive therapy after failure of venetoclax-inclusive, less-intensive therapy4
Editorial Board3
Response to azacitidine in patients with chronic myelomonocytic leukemia according to overlap myelodysplastic/myeloproliferative neoplasms criteria3
Topic: AS08-Treatment/AS08b-Current treatment options – Lower risk MDS: LUSPATERCEPT IN THE TREATMENT OF MDS PATIENTS. A SINGLE CENTER EXPERIENCE3
Intensity of induction regimen and outcomes among adults with Ph+ALL undergoing allogeneic hematopoietic stem cell transplantation3
Topic: AS01-Diagnosis/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression): MUTATIONS OF SF3B1 GENE AND ITS SIGNIFICANCE ON PATIENTS WITH MYELODYSPASTIC SYNDROMES (MDS)3
The variable biological signature of refractory cytopenia of childhood (RCC), a retrospective EWOG-MDS study3
A comprehensive comparison between TBI vs non-TBI-based conditioning regimen in pediatric patients with acute lymphoblastic leukemia: A systematic review and meta-analysis3
BuCyE can safely replace BEAM as a conditioning regimen for autologous stem cell transplantation in the treatment of refractory and relapsed lymphomas3
Easier and more explanatory indices by integrating leukocyte lymphocyte ratio (LLR) and prognostic nutritional index (PNI) to IPS systems in cases with classical Hodgkin lymphoma3
Characteristics and survival outcomes of patients with myelodysplastic syndromes with isolated 11q deletion3
Ruxolitinib for chronic steroid-refractory graft versus host disease: a single center experience3
Topic: AS07-Singular Entities/Subtypes/AS07c-Hereditary MDS including predisposition syndromes: GERMLINE PREDISPOSITION TO MYELOID MALIGNANCIES IN A CONSECUTIVE COHORT OF 183 PATIENTS3
Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML3
Comparison of 3-month cytogenetic and molecular assays for early assessment of long-term clinical impact after BCR-ABL1 tyrosine kinase inhibitor treatment in chronic myeloid leukemia3
Topic: AS08-Treatment/AS08k-Supportive care - Transfusion medicine and MDS3
Topic: AS04-MDS Biology and Pathogenesis/AS04b-Clonal diversity & evolution3
Should patients with acute myeloid leukemia treated with venetoclax-based regimens receive antifungal prophylaxis?3
EPSTEIN-BARR VIRUS ORCHESTRATE THE TUMOR MICROENVIRONMENT OF BURKITT LYMPHOMA3
CRIP1 supports the growth and migration of AML-M5 subtype cells by activating Wnt/β-catenin pathway3
Clonal hematopoiesis: Molecular and clinical implications3
Improved resolution of phenotypic subsets in human T-ALL by incorporation of RNA-seq based developmental profiling3
Topic: AS01-Diagnosis/AS01a-Cytomorphology: AUTOMATED DIGITAL TOOL FOR MDS AND MDS/MPN CLASSIFICATION USING WHO AND ICC: INTERNATIONAL GUIDELINES WORKING GROUP ON MDS DIAGNOSIS, PROGNOSIS, AND GERMLIN3
Central nervous system involvement in adult acute myeloid leukemia patients3
Prognostic role of TNF alpha, LT alpha, MDR1 and codon 72 Tp53 gene polymorphisms on multiple myeloma Egyptian patients3
Optimal therapeutic strategies in relapsed/refractory AML with prior exposure to venetoclax-based therapy3
Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation/inflammation: ROUTINE INFLAMMATORY MARKERS ARE ELEVATED IN MYELODYSPLASTIC SYNDROMES AT PRESENTATION3
The impact of tyrosine kinase inhibitors on allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia3
Clinical and molecular characteristics associated with Vitamin C deficiency in myeloid malignancies; real world data from a prospective cohort3
Effect of cumulative daunorubicin dose on cardiotoxicity after allogeneic stem cell transplantation3
CLINICAL SPECTRUM OF PRECURSOR B-CELL LYMPHOBLASTIC MALIGNANCIES: A LARGE COHORT STUDY OF 364 PEDIATRIC PATIENTS3
Rapid improvement in symptoms and physical function following ibrutinib initiation in chronic lymphocytic leukemia and the associated changes in plasma cytokines3
Presentation name: TGFbeta pathway targeting3
Topic: AS04-MDS Biology and Pathogenesis/AS04g-Epigenetic deregulation3
Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: IMPROVED PROGNOSIS OF PATIENTS WITH MDS OVER FOUR DECADES: ANALYSIS FROM THE GERMAN MDS REGISTRY3
Topic: AS01-Diagnosis/AS01a-Cytomorphology: NON-INVASIVE WEB-BASED DIAGNOSTIC ALGORITHM FOR MDS – MODEL PERFORMANCE AND VALIDATION3
Prediction of deep molecular response in chronic myeloid leukemia using supervised machine learning models3
Topic: AS04-MDS Biology and Pathogenesis/AS04c-MDS Mouse models (GEMMS, PDX): MAMMALIAN DIAPHANOUS-RELATED FORMIN 1 IS REQUIRED FOR MAINTAINING HEMATOPOIETIC STEM CELL QUIESCENCE AND SURVIVAL VIA REGU3
Chronic myeloid leukemia, BCR-ABL1-positive, carrying NPM1 mutation – First case series from a single institution3
Efficacy and safety of mitoxantrone, etoposide, and cytarabine for treatment of relapsed or refractory acute myeloid leukemia3
Single vs double umbilical cord blood transplantation in acute leukemia: Systematic review and meta-analysis3
Effects of conventional interventions on early-stage primary cutaneous marginal zone lymphoma: A population-based study3
Validation of Molecular International Prognostic Scoring System (IPSS-M) in myelodysplastic/myeloproliferative neoplasms, not otherwise specified (MDS/MPN-NOS)3
Sparsity regularization enhances gene selection and leukemia subtype classification via logistic regression3
Topic: AS04-MDS Biology and Pathogenesis/AS04f-Gene expression profiling3
The relationship between clinical prognostic factors, microvascular density, and tumor-infiltrating lymphocytes with CD47 and SIRPα expression in diffuse large B cell lymphomas3
PRMT5 inhibitors for lower-risk myelodysplasia: Is there anywhere to move?3
MOLECULAR GENETICS ANALYSIS OF B-CELL PRECURSOR LYMPHOMA IN PEDIATRIC AND ADOLESCENT PATIENTS REVEALS HIGH FREQUENCY OF KMT2A TRANSLOCATIONS3
Presentation name: What we learn from real-world registries3
MLL1 inhibition reduces IgM levels in Waldenström macroglobulinemia3
Clinical features and management of germline CEBPA-mutated carriers2
Circ_0005615 enhances multiple myeloma progression through interaction with EIF4A3 to regulate MAP3K4 m6A modification mediated by ALKBH52
MDS and AML show elevated fractions of CD34-positive blast cell populations with a high anti-apoptotic versus proliferation ratio2
LONG TERM PULMONARY AND CARDIAC FUNCTION AFFECTION AMONG NON-HODGKIN LYMPHOMA2
Midkine inhibitor (iMDK) induces apoptosis of primary effusion lymphoma via G2/M cell cycle arrest2
Poor prognosis of SRSF2 gene mutations in patients treated with VEN-AZA for newly diagnosed acute myeloid leukemia2
Topic: AS08-Treatment/AS08f-Clinical trials – Phase II-III: EFFICACY AND SAFETY OF ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN THE CMML SUBPOPULATION FROM PHASE 2 AND ASCERTAIN PHASE 3 STUDIES2
Topic: AS04-MDS Biology and Pathogenesis/AS04b-Clonal diversity & evolution: ANALYSIS OF CLONAL EVOLUTION IN MYELODYSPLASTIC SYNDROMES USING DNA-SINGLE CELL ANALYSIS2
Maintenance therapy with hypomethylating agents for patients with acute myeloid leukemia in first remission not eligible for allogeneic hematopoietic cell transplantation: A systematic review and meta2
Myelodysplastic neoplasm with del(11q). Rara Avis.2
Topic: AS04-MDS Biology and Pathogenesis/AS04f-Gene expression profiling: CHARACTERIZATION OF THE TRANSCRIPTIONAL ALTERATIONS OF PATIENTS WITH DEL(5Q) MYELODYSPLASTIC SYNDROME2
Cytarabine and EIP co-administration synergistically reduces viability of acute lymphoblastic leukemia cells with high ERG expression2
Effects of neuromuscular electrical stimulation combined with resistance exercises on muscle strength in adult hematological cancer patients: A randomized controlled study2
Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation/inflammation: BONE MARROW MICROENVIRONMENT CHANGES IN MYELODYSPLASTIC NEOPLASMS AND ITS RELATIONSHIP WITH CLONAL HEMATOPOIESIS2
Topic: AS01-Diagnosis/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression): GENOMIC CLASSIFICATION OF MYELODYSPLASTIC SYNDROMES2
Pre-existing cytopenia heralding de novo acute myeloid leukemia: Uncommon presentation of NPM1-mutated AML in a single-center study2
UPFRONT PEMBROLIZUMAB IN THERAPY OF NIJMEGEN BREAKAGE SY (NBS) PATIENT WITH HODGKIN LYMPHOMA DEMONSTRATED HIGH EFFICACY AND WAS WELL TOLERATED2
Gene regulatory mechanisms of T cell exhaustion in diffuse large B cell lymphoma based on single-cell transcriptome data2
Outcomes and hospitalization patterns of patients with acute myelogenous leukemia treated with frontline CPX-351 or HMA/venetoclax2
Topic: AS04-MDS Biology and Pathogenesis/AS04g-Epigenetic deregulation: SINGLE CELL PROTEOMICS IDENTIFIES DISTINCT EPIGENETIC PERTURBATIONS AND BIOMARKERS TO PREDICT RESPONSIVENESS TO AZACITIDINE IN M2
Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: COMPARISON OF PROGNOSTICATION BY IPSS-M, IPSS-R AND AIPSS-MDS IN THE CONTEXT OF LIMITED AVAILABILITY OF MOLECULAR DATA IN2
Topic: AS04-MDS Biology and Pathogenesis/AS04d-Somatic mutations: TP53 ALLELIC STATE DID NOT INFLUENCE THE PROGNOSIS IN MYELODYSPLASTIC SYNDROMES (MDS) WITH 5Q DELETION2
0.074594020843506